Compare Micron Technology, Inc. (MU) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs 10X Genomics Inc — how do they compare? Micron Technology, Inc. trades at $1,057.06 (market cap $1.17T), while 10X Genomics Inc trades at $78.75 (market cap $10.07B). The key difference: Micron Technology, Inc. is far larger — about 116.2× 10X Genomics Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 48 Days and 10X Genomics Inc for 92 Days on average.
| MU | TXG | |
|---|---|---|
Market Cap | $1.17T | $10.07B |
Volume | 29,425,906 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $1.21K | $97.74 |
52-Week Low | $181.60 | $11.48 |
Typical Hold Time | 48 Days | 92 Days |
Enterprise Value | $1.13T | $9.59B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,088, up 4.06% today, reflecting strong momentum amid a bullish technical outlook. The stock shows robust fundamentals with a P/E of 14.64, net income margin of 63.8%, and three consecutive quarterly earnings beats. Recent news highlights multi-year growth driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030.
Outlook remains positive with analyst consensus favoring Buy ratings (82.85%) and a $1,590 price target. Key risks include cyclical memory pricing and slowing growth projections, but institutional sentiment and cash flow trends support upside potential for investors seeking AI-driven semiconductor exposure.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
